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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing has lagged in many countries
because of test kit shortages and analytical process bottlenecks. This study investigated the feasibility
and accuracy of a sample pooling approach for wide-scale population screening for coronavirus disease
2019. A total of 940 nasopharyngeal swab samples (934 negative and 6 positive) previously tested for
SARS-CoV-2 were deidentified and assigned random numbers for analysis, and 94 pools of 10 samples
each were generated. Automated RNA extraction, followed by RT-PCR, was performed in a 96-well plate.
Positive pools were identified, and the individual samples were reanalyzed. Of the 94 pools/wells, four
were positive [Ct values: N (22.7 to 28.3), ORF1ab (23.3 to 27.2), and internal control (34.4 to 35.4)].
The 40 samples comprising the four pools were identified and reanalyzed individually; six samples were
positive, with Ct values of N gene, ORF1ab, and internal control comparable to their respective wells.
Additional experiments were performed on samples with high Ct values, and overall results showed
91.6% positive and 100% negative agreement compared with individual testing approach. Thus, 940
samples were tested in 148 reactions compared with 940 reactions in routine screening. The sample
pooling strategy may help catch up with testing needs and minimal turnaround times and facilitate
enormous savings on laboratory supplies, extraction, and PCR kits currently in short supply.
(J Mol Diagn 2020, 22: 1294e1299; https://doi.org/10.1016/j.jmoldx.2020.07.001)
The outbreak of coronavirus disease 2019 [COVID-19; caused
by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2)] is now a pandemic that has caused mass disruption of
the world order, impacting public health care systems, social
lifestyle, governance, and economics. Since its identification in
the region of Wuhan, China, >6.24 million confirmed cases
with>374,452 COVID-19erelated deaths have been reported
globally (https://coronavirus.jhu.edu/map.html, last accessed
June 1, 2020). The incidence of disease is highly varied
across the globe, with the incidence rates ranging from 5618
per million in United States, 617 per million in Spain, and
approximately 50 per million in Africa, compared with the
global incidence rate of 816 per million (https://www.
worldometers.info/coronavirus/#countries, last accessed June
1, 2020).
To contain the spread of disease, multidisciplinary strate-
gies have been launched in different regions of the world,
including implementing social distancing, maintaining per-
sonal hygiene, contact tracing, and implementing quarantine,
travel restrictions, and lockdowns.1 A widely accepted
method, although not effectively implemented as a measure
to control its spread, is testing for SARS-CoV-2, typically
utilizing nasopharyngeal swab specimens. Patients tested
positive require appropriate clinical management by either
effective isolation or quarantine at home for mild symptoms
or within health care facilities for moderate to severe
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symptoms. Wide-scale testing approaches, such as those
implemented in the Republic of Korea, have resulted in great
success at reducing community spread and lowering mor-
tality rates.2 In addition, wide-scale testing provides more
informative epidemiologic data for drafting policies on dis-
ease monitoring and control. Currently, at least 85 manu-
facturers of diagnostic assays have received Emergency Use
Authorization from the Federal Drug and Food Administra-
tion for COVID-19 testing (https://www.fda.gov/medical-
devices/emergency-situations-medical-devices/emergency-use-
authorizations#COVID19ivd, last accessed June 1, 2020).
However, testing has lagged behind in many countries
because of various factors, most significant being supply
chain issues with lack of reagents and adequate test kits.
Therefore, many patients (both symptomatic and asymp-
tomatic) remain untested and hence are potentially contrib-
uting to community spread of the virus. Furthermore, many
countries, including high-income countries, have logically
resorted to prioritize testing for the hospitalized, symptom-
atic, and high-risk population. With this approach, absence
of testing or long turnaround times among exposed but
asymptomatic individuals and patients exhibiting mild
symptoms have been observed, a factor that likely contrib-
utes to exponential community spread.
This article proposes a mass population screening
approach, based on sample pooling strategy for rapid and
wide-scale population screening that may be adopted by
laboratories currently using RT-PCRebased methods to test
for SARS-CoV-2. The strategy proposed leverages existing
high-throughput systems that employ high analytically
sensitive [limit of detection (LOD), 5 to 20 copies/mL] real-
time PCR chemistries, coupled with pooling of samples
based on current COVID-19 incidence rates. Pooling of
samples compared with individual testing has been inves-
tigated previously, such as in screening blood donations and
infectious and genetic diseases.3e5 Pooling, when carefully
executed, has been found to be useful and more cost-
effective for estimating incidence rates in specific cases.6
The advantages of this approach include the potential to
catch up with huge testing deficits, reducing turnaround
times, and, most important, ensuring enormous savings
through the most efficient use of RNA extraction and/or
testing kits, which even today are in significant short supply.
Routine Screening versus Mass Population
Screening Approach for COVID-19
The RT-PCRebased methods have two primary components:
RNA extraction from clinical specimens and RT-PCRebased
detection of SARS-CoV-2 nucleic acid region(s). The nucleic
acid targets used in most commercial kits are based on primer/
probe sequences published by either theUSorChinaCDC. In a
routine screening approach, the number of samples that could
be tested in a 96-well RT-PCR plate varies from 30 (CDC;
https://www.fda.gov/media/134919/download, last accessed
June 1, 2020) to 94 (PerkinElmer, Inc.; https://www.fda.gov/
media/136407/download, last accessed June 1, 2020).
However, as these are sensitive methods with LOD as low as
5 to 20 copies/mL, an alternate, more effective approach
may be adopted for mass population screening for COVID-
19. In this approach, an equal aliquot from 10 samples can
be pooled together after collection, and processed for nucleic
acid extraction and RT-PCR analysis. The number of
reactions/runs required to test 940 patients in routine
screening versus mass population screening approach based
on the incidence of COVID-19 in the respective countries
(Table 1). Thus, the mass screening approach in United
States has a potential to test 940 patients in 118 reactions/2
runs compared with 940 reactions/10 runs using PerkinElmer
assay. Similarly, 940 patients can be tested in 133 reactions/
7 runs compared with 940 reactions/32 runs using CDC
assay. To demonstrate the feasibility of the mass population
screening approach, a laboratory-based blinded study with
940 samples was performed using PerkinElmer assay.
Materials and Methods
Assay for the Detection of SARS-CoV-2
The assay is based on RNA extraction, followed by TaqMan-
based RT-PCR assay, to conduct in vitro transcription of
SARS-CoV-2 RNA, DNA amplification, and fluorescence
detection (PerkinElmer Inc., Waltham,MA). The assay targets
specific genomic regions of SARS-CoV-2: nucleocapsid (N)
gene andORF1ab. The TaqMan probes for the two amplicons
are labeled with 6-carboxyfluorescein and 6-carboxy-X-
rhodamine fluorescent dyes, respectively, to generate target-
specific signals. The assay includes an RNA internal control
(bacteriophage MS2) that serves as assay control from nucleic
acid extraction to fluorescence detection. The internal control
probe is labeledwithVictoriafluorescent dye to differentiate its
fluorescent signal from SARS-CoV-2 targets.
Routine Screening Approach
In routine screening, a batch of 94 samples were processed
for the detection of SARS-CoV-2. In brief, an aliquot of 300
mL from each sample, including positive and negative con-
trols, was added to respective wells in a 96-well plate. To
each well, 5 mL internal control, 4 mL poly(A) RNA, 10 mL
proteinase K, and 300 mL lysis buffer 1 were added. The
plate was placed on a semiautomated instrument (chemagic
360 instrument; PerkinElmer, Inc.) following manufacturer’s
protocol. The nucleic acid was extracted in a 96-well plate,
with an elution volume of 60 mL. From the extraction plate,
40 mL of extracted nucleic acid and 20 mL of RT-PCR master
mix were added to the respective wells in a 96-well PCR
plate. The PCR method was set up as per manufacturer’s
protocol on Quantstudio3 (Thermo Fisher Scientific, Wal-
tham, MA). The samples resulted as positive or negative
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based on the Ct values specified by the manufacturer
(Supplemental Table S1).
Mass Population Screening Approach
Sample Selection, Blinding, and Pooling of Samples: Step 1
In mass population screening (Figure 1), under the institu-
tional review boardeapproved protocol, 940 nasopharyn-
geal swab samples previously tested for SARS-CoV-2 were
de-identified and assigned random numbers (performed by
N.S.S.). The 940 samples contained 934 negative and 6
positive samples. From this, 94 pools of 10 samples each
were generated and given a unique number (performed S.A.,
who was blinded to the initial sample preparation).7,8 To
pool 10 samples, 35 mL of each sample was aliquoted into a
vial (350 mL). The vial was vortex mixed and briefly spun,
and 300 mL of pooled sample was transferred to the sample
deep-well plate. The samples were processed for down-
stream extraction and RT-PCR, as stated in the routine
screening approach (Supplemental Table S2).
Identifying the Positive Sample: Step 2
Pool(s) that resulted positive were identified, and the 10
samples comprising each positive pool were retrieved and
processed for downstream extraction and RT-PCR analysis
for the identification of the positive sample(s). The positive
sample(s) were identified based on the Ct value specified by
the manufacturer. In addition, one negative pool was
selected randomly, and each sample was re-analyzed indi-
vidually as a quality control measure.
Table 1 Comparison of Individual Sample Screening versus Mass Population Screening Approach in the United States for COVID-19
SARS-CoV-2
detection kit Screening approach
Patients
tested
in one
run/plate, N
LOD,
copies/mL
Probability
of number of samples
positive in US
population
screening
Additional
reactions to be
performed, N
940 Patients
tested in
following
number
of reactions
Runs to
screen 940
patients, N
PerkinElmer Inc. Individual sample screening 94 20 0.51 0 940 10
Mass population screening 940 200 5.16 20 118 2
US CDC Individual sample screening 30 5e10 0.033 0 940 32
Mass population screening 300 50e100 0.33 10 133 7
COVID-19, coronavirus disease 2019; LOD, limit of detection; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 1 Study flowchart. IC, internal control; ID, identifier.
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Results
In step 1, the quality control of negative and positive sample
was observed to be within the range recommended by the
manufacturer. Of the 94 pools/well, 4 resulted positive, with
Ct values for the two target genes within the range as follows:
N (22.7 to 28.3), ORF1ab (23.3 to 27.2), and internal control
(34.4 to 35.4) (Figure 2). The remaining 90 wells resulted as
negative, with undetermined Ct values for N and ORF1ab
gene. In step 2, 40 samples comprising the four pools were
identified and re-analyzed individually, with 6 samples
resulting positive (3 samples in pool 23 and 1 sample each in
pools 11, 59, and 90), with the Ct values of N gene, ORF1ab,
and internal control comparable to their respective pools/well
(Figure 3, Table 2). All samples in the negative pool were
confirmed as negative. Thus, the 6 positive samples were
correctly identified, as the 940 samples selected contained
934 negative and 6 positive samples. The data files from
steps 1 and 2 are provided as Supplemental Tables S3 and
S4, respectively. A supplement study was performed on
six pools, each containing nine negative samples and one
positive sample with high Ct values (N: 30.9 to 39.6;
ORF1ab: 30.7 to 38.5). Each pool was processed for RNA
extraction and RT-PCR analysis. All pools, except the
pool containing the sample with very high Ct (N: 39.6;
ORF1ab: 38.5) was not detected (Supplemental Table
S5). Therefore, 1000 samples resulted in an overall
91.6% positive percentage agreement and 100% negative
percentage agreement compared with individual testing
approach.
Figure 2 Step 1: 94 pools, each composed of 10 samples, were screened on an RT-PCRebased method. Of these 94 pools, 4 (ie, pools 11, 23, 59, and 90)
showed amplification of severe acute respiratory syndrome coronavirus 2 and N and ORF1ab genes. Representative amplification curves for the negative,
positive control, and four positive pools are shown. IC, internal control.
Figure 3 Step 2: The four positive pools were individually tested; of these 40 samples, 6 showed amplification of severe acute respiratory syndrome
coronavirus 2 and N and ORF1ab genes. Representative amplification curves for the individual positive samples (three samples in pool 23 and one sample each
in pools 11, 59, and 90) from the respective positive pools are shown. IC, internal control.
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Discussion
The COVID-19 pandemic has resulted in an overwhelming
number of infected patients, leading to a tremendous burden
on health care resources to the extent of outstripping the
current production capabilities for supplies. Innovative ideas
in specimen collection, isolation, respiratory support, and
other patient care plans have been implemented. Scaling up
testing has been identified as a key component to manage
the pandemic.9 Laboratories and manufacturers of test kits
across the world have also responded by ramping up testing.
However, more innovative approaches are needed for wide-
scale population testing and to side step the foreseeable
shortages in test kits. This study demonstrates that pooling
patient samples and testing them on high-sensitivity, high-
throughput systems are both practical and accurate.
In this proof-of-concept study with 40 samples, four pools
were formed with 10 samples (nine negative and one positive
sample) in each pool, and processed for extraction and RT-
PCR. In all four pools, a positive result was obtained. To
investigate the effect of dilution, samples were selected with
both high and low viral load (based on Ct values). On
analysis, a positive result was obtained from all four pools,
and the Ct value of approximately 3 points higher was
observed for pools compared with individually tested sam-
ples. Furthermore, in validation studies, contrived samples
(spiking 1 mL positive sample into 299 mL negative sample)
were observed to result in positive identification by RT-PCR.
These pilot studies indicated that patient samples probably
contain viral loads that are sufficiently high as to be above the
LOD, even with a 1:300 dilution (N.S.S., A.K.M., S.A.,
A.N., and R.K., unpublished data). However, as the viral load
varies with respect to the day of infection and among in-
dividuals, pooling 10 samples (1:10 dilution) seems ideal as
the LOD in pooling experiment will remain from 50 to 200
copies/mL for CDC or PerkinElmer assays, respectively.
In the primary study using 940 pooled samples, four wells
representing the four pools with positive samples were
accurately identified. In the second step, all 40 samples in
these pools were retrieved and tested individually. The
strategy was able to identify the pools with positive sam-
ple(s), and the one-step dissection accurately established the
positive samples with comparable Ct values in the pool and
individually tested samples. As a quality control measure,
one pool identified as negative was randomly selected and
the 10 samples were tested individually, which resulted as
negative for each individual sample. A comparison of the
pooling and individual testing strategies shows that it would
take at least 10 extraction runs, 10 PCR runs (96-well plate
format), and at least 30 hours to process all of the samples.
The pooling strategy, on the other hand, required only two
extraction runs, two PCR runs, and 6 hours for all 940
samples. Results for all the samples in the negative wells
can potentially be released after the first run, whereas those
in the positive wells would proceed for a second round of
extraction and PCR in the typical individual testing scheme.
A laboratory already conducting high-throughput testing for
COVID-19 can effectively multiply its output by a factor
proportional to the number of pooled samples. The sample
pooling strategy can have high impact in acquisition of
wide-scale epidemiologic data on the spread of SAR-CoV-2
across the globe.
An important consideration in the pooling strategy is the
potential for false-negative results because of dilution of
samples with low viral loads (LOD < 200 copies/mL). To
highlight this point, a supplement study was performed on six
samples with high Ct values (N: 30.9 to 39.6; ORF1ab: 30.7
to 38.5). Each positive sample was pooled with nine negative
samples forming six pools. Each pool was processed for
RNA extraction and RT-PCR analysis. All pools, except the
pool containing the sample with high Ct (N: 39.6; ORF1ab:
38.5), were not detected (Supplemental Table S5). Another
challenge to this approach is inaccurate designation of indi-
vidual and pooled samples within the 96-well plate, resulting
in sample mix-up. To minimize this, use of a minimum of
two identifiers and well-documented workflows to ensure
traceability of all pooled samples is essential. In addition, use
of bar code readers and automated sample processing would
minimize the chances of such a mix-up. Furthermore,
selected samples from randomly selected negative pool(s)
should also be analyzed individually as a quality control
monitor. In the current study, all samples in one negative
result pool/well were retested and were found to be in
agreement with individually tested samples.
In terms of cost analysis, 1 million individuals can be
tested for $9.1 million with the proposed mass population
Table 2 The Ct Values from the Pools Resulting Positive in Step 1, and the Individual Positive Samples Identified in Step 2, with the Mass
Population Screening Approach
Pool ID
Pooled sample Ct (step 1)
Individual sample ID
Individual sample Ct (step 2)
N gene (Ct) ORF1ab (Ct) IC (Ct) N gene (Ct) ORF1ab (Ct) IC (Ct)
11 22.7 23.4 34.4 6609 19.2 19.4 36.5
23 27.8 26.7 35.4 2452 25.9 24.6 34.5
3 28.2 25.6 34.7
9189 23.4 21.6 34.5
59 24.0 23.3 35.3 7340 19.7 17.9 34.7
90 28.3 27.2 35.1 40 23.8 21.9 34.9
IC, internal control; ID, identifier.
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screening approach compared with $58 million with routine
screening. More important, however, is the potential to
massively increase the number of individuals tested using
the same quantity of reagents/test kits. This is a critical
advantage given the short supply of test kits, a fact with the
disparity that ensues especially in low- and middle-income
countries. The direct savings on reagent and test kits are
complemented by indirect savings on laboratory supplies,
including personal protective equipment, that are needed to
perform testing on these infectious clinical samples. These
savings will enhance sustainable laboratory operations
throughout the pandemic or can be deployed to laboratories
that are facing dire constraints in supplies.
In conclusion, this unprecedented crisis requires innovative
solutions at all levels. The strategy proposed herein leverages
existing high-throughput systems, which employ analytically
high-sensitive RT-PCR chemistries, coupled with pooling of
samples based on current COVID-19 incidence rates. This
study analyzed 1000 samples in a pooled approach using
only two extraction and PCR runs and achieved 91.6%
positive percentage agreement and 100% negative percentage
agreement. To optimize the number of pooled samples, real-
time region-specific data in websites, such that hosted by the
Center for Systems Science and Engineering at Johns Hop-
kins University (Baltimore, MD), are helpful. In addition,
robust validation and knowledge of the analytical perfor-
mance of the assay to be adopted as well as regional/labo-
ratory positivity rates are critical in this approach. The
number of samples pooled is inversely proportional to the
analytical sensitivity of the assay and the local positivity
rate.10,11 The advantages of this innovative approach include
potential of catching up with testing, clearing backlogged
samples, reducing turnaround times, and ensuring enormous
savings on RNA extraction and/or testing kits and laboratory
supplies that are in short supply. This would relieve the
pressure mounting on laboratories for increased testing,
hopefully making a significant contribution to control of this
pandemic. In addition, this strategy may come in handy for
effective and consistent disease surveillance as many states
and countries begin to reopen businesses, airports, public
gatherings, and work environments. Monitoring spikes in the
number of cases in groups of individuals in the same envi-
ronment will facilitate rapid and early containment.
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